In an award-winning attempt to get closer to patients, Samsung Bioepis has replaced harsh typography with white backgrounds and gentle shapes on its new biosimilar packaging.
Can you make a biosimilar package more appealing for a patient? What would you change? Those were the questions that designers at Samsung Bioepis pondered as they sought unifying design elements they could use across their drug portfolio while still enabling patients and doctors to distinguish one product from another.
They appear to have succeeded. The Incheon, Republic of Korea—based company won 2 prestigious Red Dot Design Awards for its soft-yet-engaging product designs that feature basic shapes and soothing colors, such as a purple, fruit-like shape for its infliximab product (Renflexis, Flixabi, Remaloce) and a fusion of green or blue circular shapes for its etanercept biosimilar (Eticovo, Brenzys, Benepali, Etoloce).
Meanwhile, Samsung Bioepis’ trastuzumab contender (Ontruzant, Samfenet) was given a solid, salmon-colored tulip-like shape.
The company called the redesign “Passion for Health: Pure Joy in Life.” It draws from tranquil, organic forms to evoke mental and physical stability in patients who are struggling with their health conditions.
“It was designed with a motive to bring out life and joy for patients with chronic illness,” Samsung Bioepis said. “The focus of the design was ‘process of healing’ by using soft graphics in order to move away from the conventional, rigid design of medicine packaging, which only serves to deliver safety information.”
Samsung Bioepis won the Brand Design & Identity and Packaging Design awards in this year’s Red Dot contest. The company has been part of a wave of biosimilar industry powering up in Republic of Korea, which has enjoyed double-digit growth for the past 5 years.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.